{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:26:51Z","timestamp":1785418011659,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-07301-5","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:14:13Z","timestamp":1759842853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of 5-hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms in treatment-resistant obsessive\u2013compulsive disorder: a comparative study with other treatment-resistant mental disorders"],"prefix":"10.1186","volume":"25","author":[{"given":"Antonio","family":"Del Casale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Francesco","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina Nicole","family":"Modesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Zocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Mancino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Angeletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferracuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Simmaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Borro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"7301_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-5-TR. American Psychiatric Association Publishing; Washington, DC; 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"7301_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"AM Ruscio","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15:53\u201363.","journal-title":"Mol Psychiatry"},{"issue":"Suppl","key":"7301_CR3","first-page":"4","volume":"53","author":"SA Rasmussen","year":"1992","unstructured":"Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry. 1992;53(Suppl):4\u201310.","journal-title":"J Clin Psychiatry"},{"key":"7301_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593\u2013602.","journal-title":"Arch Gen Psychiatry"},{"key":"7301_CR5","doi-asserted-by":"crossref","unstructured":"Bandelow B, Allgulander C, Baldwin DS, Costa DL da C, Denys D, Dilbaz N, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2023;24:118\u201334.","DOI":"10.1080\/15622975.2022.2086296"},{"key":"7301_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2174\/1570159X16666180813155017","volume":"17","author":"A Del Casale","year":"2019","unstructured":"Del Casale A, Sorice S, Padovano A, Simmaco M, Ferracuti S, Lamis DA, et al. Psychopharmacological treatment of Obsessive-Compulsive Disorder (OCD). Curr Neuropharmacol. 2019;17:710\u201336.","journal-title":"Curr Neuropharmacol"},{"key":"7301_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12863-015-0325-6","volume":"17","author":"CL Ruble","year":"2016","unstructured":"Ruble CL, Smith RM, Calley J, Munsie L, Airey DC, Gao Y, et al. Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons. BMC Genet. 2016;17:16.","journal-title":"BMC Genet"},{"issue":"7 Pt 1","key":"7301_CR8","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1523\/JNEUROSCI.15-07-04885.1995","volume":"15","author":"QS Zhu","year":"1995","unstructured":"Zhu QS, Chen K, Shih JC. Characterization of the human 5-HT2A receptor gene promoter. J Neurosci Off J Soc Neurosci. 1995;15(7 Pt 1):4885\u201395.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"7301_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.biopsych.2005.12.018","volume":"61","author":"RL Myers","year":"2007","unstructured":"Myers RL, Airey DC, Manier DH, Shelton RC, Sanders-Bush E. Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol Psychiatry. 2007;61:167\u201373.","journal-title":"Biol Psychiatry"},{"key":"7301_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.biopsych.2012.09.028","volume":"73","author":"RM Smith","year":"2013","unstructured":"Smith RM, Papp AC, Webb A, Ruble CL, Munsie LM, Nisenbaum LK, et al. Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol Psychiatry. 2013;73:546\u201354.","journal-title":"Biol Psychiatry"},{"key":"7301_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.biopsych.2004.06.020","volume":"56","author":"MJ Parsons","year":"2004","unstructured":"Parsons MJ, D\u2019Souza UM, Arranz M-J, Kerwin RW, Makoff AJ. The -1438A\/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry. 2004;56:406\u201310.","journal-title":"Biol Psychiatry"},{"key":"7301_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jad.2020.06.016","volume":"275","author":"GF Mattina","year":"2020","unstructured":"Mattina GF, Samaan Z, Hall GB, Steiner M. The association of HTR2A polymorphisms with obsessive-compulsive disorder and its subtypes: a meta-analysis. J Affect Disord. 2020;275:278\u201389.","journal-title":"J Affect Disord"},{"key":"7301_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1124\/mol.66.5.1293","volume":"66","author":"LA Hazelwood","year":"2004","unstructured":"Hazelwood LA, Sanders-Bush E. His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol Pharmacol. 2004;66:1293\u2013300.","journal-title":"Mol Pharmacol"},{"key":"7301_CR14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.neuroimage.2003.10.046","volume":"21","author":"KH Adams","year":"2004","unstructured":"Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugb\u00f8l S, et al. A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage. 2004;21:1105\u201313.","journal-title":"Neuroimage"},{"key":"7301_CR15","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1002\/hbm.25138","volume":"41","author":"M Spies","year":"2020","unstructured":"Spies M, Nasser A, Ozenne B, Jensen PS, Knudsen GM, Fisher PM. Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels. Hum Brain Mapp. 2020;41:4518\u201328.","journal-title":"Hum Brain Mapp"},{"key":"7301_CR16","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3390\/biomedicines11072088","volume":"11","author":"A Del Casale","year":"2023","unstructured":"Del Casale A, Simmaco M, Modesti MN, Zocchi C, Arena JF, Bilotta I, et al. DRD2, DRD3, and HTR2A single-nucleotide polymorphisms involvement in high treatment resistance to atypical antipsychotic drugs. Biomedicines. 2023;11:2088.","journal-title":"Biomedicines"},{"key":"7301_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","volume":"30","author":"S Pallanti","year":"2006","unstructured":"Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:400\u201312.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"7301_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1192\/bjp.166.4.424","volume":"166","author":"M Piccinelli","year":"1995","unstructured":"Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry J Ment Sci. 1995;166:424\u201343.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"7301_CR19","doi-asserted-by":"publisher","first-page":"1065812","DOI":"10.3389\/fpsyt.2023.1065812","volume":"14","author":"K Swierkosz-Lenart","year":"2023","unstructured":"Swierkosz-Lenart K, Dos Santos JFA, Elowe J, Clair A-H, Bally JF, Riquier F, et al. Therapies for obsessive-compulsive disorder: current state of the art and perspectives for approaching treatment-resistant patients. Front Psychiatry. 2023;14:1065812.","journal-title":"Front Psychiatry"},{"key":"7301_CR20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/archpsyc.1996.01830090031005","volume":"53","author":"FM Quitkin","year":"1996","unstructured":"Quitkin FM, McGrath PJ, Stewart JW, Ocepek-Welikson K, Taylor BP, Nunes E, et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53:785\u201392.","journal-title":"Arch Gen Psychiatry"},{"key":"7301_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","volume":"80","author":"J Lundberg","year":"2023","unstructured":"Lundberg J, Cars T, L\u00f6\u00f6v S-\u00c5, S\u00f6derling J, Sundstr\u00f6m J, Tiihonen J, et al. Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study. JAMA Psychiat. 2023;80:167\u201375.","journal-title":"JAMA Psychiat"},{"key":"7301_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","volume":"27","author":"OD Howes","year":"2022","unstructured":"Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry. 2022;27:58\u201372.","journal-title":"Mol Psychiatry"},{"key":"7301_CR23","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Major Depressive Disorder: Developing Drugs for Treatment Guidance for Industry. Food and Drug Administration; 2018."},{"key":"7301_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216\u201329.","journal-title":"Am J Psychiatry"},{"key":"7301_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175\u201391.","journal-title":"Behav Res Methods"},{"key":"7301_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149\u201360.","journal-title":"Behav Res Methods"},{"key":"7301_CR27","unstructured":"IBM Corp. IBM SPSS Statistics for Macintosh. 2021."},{"key":"7301_CR28","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1086\/503820","volume":"78","author":"FJ McMahon","year":"2006","unstructured":"McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804\u201314.","journal-title":"Am J Hum Genet"},{"key":"7301_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.euroneuro.2009.08.006","volume":"20","author":"S Lucae","year":"2010","unstructured":"Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, M\u00fcller-Myhsok B, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2010;20:65\u20138.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"7301_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.pnpbp.2013.05.011","volume":"45","author":"T Niitsu","year":"2013","unstructured":"Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:183\u201394.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"7301_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1089\/cap.2018.0004","volume":"28","author":"P Gass\u00f3","year":"2018","unstructured":"Gass\u00f3 P, Bl\u00e1zquez A, Rodr\u00edguez N, Boloc D, Torres T, Mas S, et al. Further support for the involvement of genetic variants related to the serotonergic pathway in the antidepressant response in children and adolescents after a 12-month follow-up: impact of the HTR2A rs7997012 polymorphism. J Child Adolesc Psychopharmacol. 2018;28:711\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"7301_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jad.2014.06.012","volume":"168","author":"J-Y Lin","year":"2014","unstructured":"Lin J-Y, Jiang M-Y, Kan Z-M, Chu Y. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014;168:430\u20138.","journal-title":"J Affect Disord"},{"key":"7301_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/YIC.0b013e328338bcf4","volume":"25","author":"M Noro","year":"2010","unstructured":"Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol. 2010;25:228\u201331.","journal-title":"Int Clin Psychopharmacol"},{"key":"7301_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4306\/pi.2013.10.2.180","volume":"10","author":"A Serretti","year":"2013","unstructured":"Serretti A, Fabbri C, Pellegrini S, Porcelli S, Politi P, Bellino S, et al. No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. Psychiatry Investig. 2013;10:180\u20139.","journal-title":"Psychiatry Investig"},{"key":"7301_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jad.2013.02.036","volume":"150","author":"N Antypa","year":"2013","unstructured":"Antypa N, Calati R, Souery D, Pellegrini S, Sentissi O, Amital D, et al. Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. J Affect Disord. 2013;150:649\u201352.","journal-title":"J Affect Disord"},{"key":"7301_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/tpj.2012.33","volume":"13","author":"FW Lohoff","year":"2013","unstructured":"Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13:464\u20139.","journal-title":"Pharmacogenomics J"},{"key":"7301_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/tpj.2011.47","volume":"13","author":"FW Lohoff","year":"2013","unstructured":"Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13:21\u20136.","journal-title":"Pharmacogenomics J"},{"key":"7301_CR38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1017\/S1461145709991027","volume":"13","author":"G Laje","year":"2010","unstructured":"Laje G, Cannon DM, Allen AS, Klaver JM, Peck SA, Liu X, et al. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol. 2010;13:715\u201324.","journal-title":"Int J Neuropsychopharmacol"},{"key":"7301_CR39","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.janxdis.2011.03.002","volume":"25","author":"M Atmaca","year":"2011","unstructured":"Atmaca M, Onalan E, Yildirim H, Yuce H, Koc M, Korkmaz S, et al. Serotonin transporter gene polymorphism implicates reduced orbito-frontal cortex in obsessive-compulsive disorder. J Anxiety Disord. 2011;25:680\u20135.","journal-title":"J Anxiety Disord"},{"key":"7301_CR40","doi-asserted-by":"publisher","first-page":"111217","DOI":"10.1016\/j.pscychresns.2020.111217","volume":"307","author":"L Hatchondo","year":"2021","unstructured":"Hatchondo L, Vall\u00e9e A, Vall\u00e9e R, Jaafari N, Maillochaud S, Naudin M, et al. Altered phospholipid and high-energy phosphate metabolism in the basal ganglia and thalamus of severe obsessive compulsive patients with treatment resistance: A phosphorus 31 nuclear magnetic resonance spectroscopy study. Psychiatry Res Neuroimaging. 2021;307:111217.","journal-title":"Psychiatry Res Neuroimaging"},{"issue":"114","key":"7301_CR41","first-page":"1603","volume":"2007","author":"M Reimold","year":"1996","unstructured":"Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study. J Neural Transm Vienna Austria. 1996;2007(114):1603\u20139.","journal-title":"J Neural Transm Vienna Austria"},{"key":"7301_CR42","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1038\/npp.2008.35","volume":"33","author":"W Zitterl","year":"2008","unstructured":"Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Wenzel T, et al. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2008;33:3126\u201334.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"7301_CR43","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.neubiorev.2017.05.029","volume":"80","author":"VM Sinopoli","year":"2017","unstructured":"Sinopoli VM, Burton CL, Kronenberg S, Arnold PD. A review of the role of serotonin system genes in obsessive-compulsive disorder. Neurosci Biobehav Rev. 2017;80:372\u201381.","journal-title":"Neurosci Biobehav Rev"},{"key":"7301_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ajmg.b.32407","volume":"171B","author":"S Taylor","year":"2016","unstructured":"Taylor S. Disorder-specific genetic factors in obsessive-compulsive disorder: a comprehensive meta-analysis. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2016;171B:325\u201332.","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet"},{"key":"7301_CR45","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/PSY.0000000000001251","volume":"85","author":"AI Hoogland","year":"2023","unstructured":"Hoogland AI, Gonzalez BD, Park JY, Small BJ, Sutton SK, Pidala JA, et al. Associations of germline genetic variants with depression and fatigue among hematologic cancer patients treated with allogeneic hematopoietic cell transplantation. Psychosom Med. 2023;85:813\u20139.","journal-title":"Psychosom Med"},{"key":"7301_CR46","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jad.2013.05.028","volume":"150","author":"G Shinozaki","year":"2013","unstructured":"Shinozaki G, Romanowicz M, Mrazek DA, Kung S. HTR2A gene-child abuse interaction and association with a history of suicide attempt among Caucasian depressed psychiatric inpatients. J Affect Disord. 2013;150:1200\u20133.","journal-title":"J Affect Disord"},{"key":"7301_CR47","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/mp.2009.19","volume":"15","author":"J Brezo","year":"2010","unstructured":"Brezo J, Bureau A, M\u00e9rette C, Jomphe V, Barker ED, Vitaro F, et al. Differences and similarities in the serotonergic diathesis for suicide attempts and mood disorders: a 22-year longitudinal gene-environment study. Mol Psychiatry. 2010;15:831\u201343.","journal-title":"Mol Psychiatry"},{"key":"7301_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/YIC.0000000000000101","volume":"31","author":"P H\u00f6fer","year":"2016","unstructured":"H\u00f6fer P, Schosser A, Calati R, Serretti A, Massat I, Kocabas NA, et al. The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment\u2013a European multicentre study. Int Clin Psychopharmacol. 2016;31:1\u20137.","journal-title":"Int Clin Psychopharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07301-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07301-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07301-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:23:45Z","timestamp":1759847025000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-07301-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7301"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07301-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee of Sant'Andrea University Hospital approved this study (protocol No. 6279\/2021). All participants provided written informed consent after receiving detailed information about the nature and objectives of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"938"}}